Impact of persistence with bisphosphonate therapy on fracture risk and costs among postmenopausal women in a managed care environment

被引：0
|
作者：
Gold, DT
Cosman, F
Frytak, J
Baran, RW
Amonkar, M
Martin, B
机构：
[1] Duke Univ, Med Ctr, Durham, NC 27706 USA
[2] Helen Hayes Hosp, W Haverstraw, NY USA
[3] i3 Magnifi, Eden Prairie, MN USA
[4] Roche Labs, Nutley, NJ USA
[5] GlaxoSmithKline Inc, Collegeville, PA USA
[6] Univ Arkansas Med Sci, Little Rock, AR 72205 USA
来源：
ARTHRITIS AND RHEUMATISM | 2005年 / 52卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S292 / S292
页数：1
相关论文
共 50 条
  • [1] Persistence with bisphosphonate therapy and fracture risk in postmenopausal women in a managed care environment.
    Gold, D
    Cosman, F
    Frytak, J
    Baran, R
    Amonkar, M
    Martin, B
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S399 - S399
  • [2] Persistence with bisphosphonate treatment and fracture risk in a managed care setting
    Cosman, F
    Gold, DT
    Frytak, J
    Baran, RW
    Amonkar, MM
    Martin, B
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2005, 12 (06): : 795 - 795
  • [3] Does dosing regimen impact persistence with bisphosphonate therapy among postmenopausal osteoporotic women?
    Cramer, JA
    Amonkar, MM
    Hebborn, A
    Suppapanya, N
    JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 : S448 - S448
  • [4] Description of fracture risk in postmenopausal women on long-term bisphosphonate therapy in primary care
    Kostoff, Matthew
    Borgelt, Laura
    Saseen, Joseph
    PHARMACOTHERAPY, 2013, 33 (10): : E183 - E183
  • [5] Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization
    Sunyecz, J. A.
    Mucha, L.
    Baser, O.
    Barr, C. E.
    Amonkar, M. M.
    OSTEOPOROSIS INTERNATIONAL, 2008, 19 (10) : 1421 - 1429
  • [6] Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization
    J. A. Sunyecz
    L. Mucha
    O. Baser
    C. E. Barr
    M. M. Amonkar
    Osteoporosis International, 2008, 19 : 1421 - 1429
  • [7] PERSISTENCE WITH BISPHOSPHONATE THERAPY AND RISK OF HIP FRACTURE
    Chodick, G.
    Shalev, V
    Sharon, Y.
    Goldstein, I
    VALUE IN HEALTH, 2011, 14 (03) : A124 - A124
  • [8] Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis
    Cramer, JA
    Amonkar, MM
    Hebborn, A
    Altman, R
    CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (09) : 1453 - 1460
  • [9] Persistence with bisphosphonate therapy and the impact of dosing frequency in patients with postmenopausal osteoporosis
    Penning-van Beest, FJA
    Goettsch, WG
    Erkens, JA
    Herings, RMC
    VALUE IN HEALTH, 2004, 7 (06) : 724 - 724
  • [10] Greater adherence to bisphosphonate therapy is associated with greater fracture risk reduction in postmenopausal women.
    Siris, E
    Rosen, C
    Silverman, S
    Abbott, T
    Barr, C
    Harris, S
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S282 - S282
12345